Professionals >

Representative Engagements >

Since its enactment in 1984, the Hatch-Waxman Act has saved consumers, insurers, and government payers over $1 trillion by enabling generic pharmaceutical companies to bring to market less expensive alternatives to branded drug products more expeditiously via the ANDA, or Abbreviated New Drug Application, process. Crowell & Moring is committed to representing generic pharmaceutical clients in ANDA litigation arising under the Hatch-Waxman Act. Our experience and know-how make us uniquely qualified to handle all stages of ANDA litigation for first filers and subsequent filers alike, from initial pre-suit investigation, counseling through trial and appeal, "at-risk" launch, and settlement. Moreover, our understanding of the regulatory framework surrounding ANDA litigation and the interplay between district courts and FDA proceedings allows us to implement successful and creative legal and regulatory strategies on behalf of our clients.

Crowell & Moring's Intellectual Property Group includes first-chair trial lawyers with years of experience litigating ANDA cases on behalf of generic pharmaceutical clients, and numerous other attorneys with significant trial experience in ANDA litigation. The ANDA litigation team includes attorneys and non-attorney professionals with technical backgrounds in biology, biotechnology, chemistry, biochemistry, organic chemistry, inorganic chemistry, and chemical engineering, as well as other related disciplines, including individuals with advanced technical degrees and Ph.D.'s in these disciplines. This depth equips Crowell & Moring with the ability to understand the complicated technical issues that often arise in these cases, as well as to translate these concepts to litigation strategies and successfully try complex ANDA litigation cases. 

Crowell & Moring's lawyers are also experienced in handling appeals of these cases before the Federal Circuit and have won many Paragraph IV litigations at the district court and appellate court levels.

Crowell & Moring's ANDA litigation attorneys include thought leaders in the biosimilars (generic biologics) field who have written and spoken extensively regarding the 2009 Biosimilar Price Competition and Innovation Act (BPCIA) and trial lawyers who have litigated biotechnology cases. With this experience, and the knowledge we have gained litigating and counseling generic pharmaceutical clients under the Hatch-Waxman Act, we are poised to guide clients through the new regulatory and emerging litigation processes under the BPCIA to successfully launch and market lower-cost biologic products. 

View More

Crowell & Moring Partner Teresa Rea Testifies Before Senate on Ways to Improve the Quality of Issued Patents (Nov.01.2019)
Firm News/Announcement
Panelists Warn Senate IP Subcommittee Against Drastic Measures On Patent Quality IPWatchdog (October 31, 2019)
In the News
Scott L. Bittman Receives Cornerstone Award for Pro Bono Work from Lawyers Alliance for New York (Oct.30.2019)
Firm News/Announcement
District of Colorado Awards “Exemplary Damages” Against Former Employee for Misappropriation of Bovine Serum Trade Secrets (October 10, 2019). Authors: Emily Tucker and Astor Heaven.
Publications
Stalking Social Media: The Rise in Counterfeit Products and Intellectual Property Concerns (October 4, 2019). Authors: David Ervin and Siri Rao.
Publications
LITIGATION NOTE: Crowell & Moring Client Agilent Successfully Rebuts Preliminary Injunction Because Patent Likely Invalid (Oct.04.2019)
Firm News/Announcement
Super Lawyers Recognizes 82 Crowell & Moring Lawyers Across United States (Sep.20.2019)
Firm News/Announcement
"What Every Start-Up Should Know Before Filing a Patent," Pennsylvania Biotechnology Center, Doylestown, PA (September 18, 2019). Speakers: Terry Rea and Mena Gaballah, PharmD.
Speech/Presentation
"EU’s Top Court Confirms Copyright for Design, but Looking Good Will Not Do the Trick," IP Insights (September 17, 2019). Contacts: Judith Bussé, Ellen Desnyder
Client Alert/Newsletter
5 Ways Ineffective Expert Witnesses Can Doom Patent Cases Law360 (September 3, 2019)
In the News

To view more News & Events for this area, please go to our desktop site.

Crowell & Moring LLP is an international law firm with more than 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, London, and Brussels.

View Desktop Site | Mobile Sitemap

Contact | Subscribe | Terms of Use/Privacy Policy | Alumni

© Crowell & Moring LLP 2019
Attorney advertising - prior results do not guarantee a similar outcome.